Duopharma Biotech (7148) Fundamentals 2026 — P/E 12.9x, Revenue Analysis | SniperIQ
Duopharma Biotech (7148) is a MY-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of RM1.2B, trading at RM1.24 on the KLS. This SniperIQ fundamentals page covers Duopharma Biotech's valuation (P/E 12.9x, P/B 1.6x), profitability (net margin 10.1%), revenue (RM932M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Duopharma Biotech's market cap?
Duopharma Biotech (7148) has a market capitalization of approximately RM1.2B, trading at RM1.24 on the KLS. Market cap moves with the live share price.
What is Duopharma Biotech's P/E ratio?
Duopharma Biotech's trailing twelve-month P/E ratio is 12.9x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Duopharma Biotech?
Duopharma Biotech runs a net profit margin of 10.1%, a gross margin of 40.0%, and an operating margin of 15.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Duopharma Biotech generate?
Duopharma Biotech reported revenue of RM932M for fiscal year 2025, with net income of RM87M and earnings per share (EPS) of 0.0909. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Duopharma Biotech pay a dividend?
Duopharma Biotech offers a trailing dividend yield of about 3.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Duopharma Biotech financially healthy?
Duopharma Biotech carries a debt-to-equity ratio of 0.64x and a current ratio of 2.62x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Duopharma Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Duopharma Biotech (7148) the key facts are: market cap RM1.2B, P/E 12.9x, revenue RM932M, 52-week range 1.18-1.57. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Duopharma Biotech's full fundamentals live
Get Duopharma Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.